61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma

RSO-021 is a first-in-class PRX3 inhibitor currently being investigated in a first-in-human phase 1/2 clinical trial called MITOPE, which is currently recruiting patients with malignant pleural effusion (MPE) arising from mesothelioma or other solid tumors (NCT05278975). Mesothelioma cells rely on buffering of mitochondrial oxidative stress through the expression and activity of mitochondrial PRX3, which is covalently inactivated by RSO-021. Inactivation of PRX3 by RSO-021 leads to increased oxidative stress and tumor cell death.

Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Brian Cunniff, Terri Messier, Victoria Gibson, David Seward, Essa Baitei, Peter Wells Jordan, Charlotte Poile, Joanna Dzialo, Aleksandra Bzura, Kudzayi Kutywayo, Apostolos Nakas, George Naumov, Dean Fennell Tags: Mesothelioma Source Type: research